TG Therapeutics Announces $100M Share Buyback Plan
ByAinvest
Thursday, Sep 4, 2025 1:52 am ET1min read
TGTX--
The new program, authorized by the company's Board of Directors, will allow TG Therapeutics to buy back shares through open-market purchases and other transactions, in accordance with applicable securities laws and subject to market conditions. This initiative follows the successful completion of the company's previously authorized $100 million share repurchase program, which was completed in August 2025.
Under the completed program, TG Therapeutics repurchased approximately 3.5 million shares of its common stock at an average price of $28.55 per share. The new program aims to continue this trend by acquiring up to an additional $100 million of TG Therapeutics' common stock.
Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, "We are pleased to announce the completion of our previously authorized $100 million share repurchase program. In the month of August, we were able to repurchase approximately $78 million of TG stock at what we believe were highly attractive prices. In addition, our Board of Directors has authorized a new $100 million repurchase program, underscoring our continued commitment to delivering value to shareholders and reflecting our conviction that current market prices do not adequately reflect the multibillion-dollar potential of BRIUMVI or the long-term growth prospects of TG Therapeutics."
The share buyback program is a strategic move that could potentially increase earnings per share and provide investors with a higher return on investment. It also signals the company's confidence in its financial health and future growth prospects.
References:
[1] https://seekingalpha.com/news/4491936-tg-therapeutics-launches-100m-share-buybacks
[2] https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-completion-existing-share-repurchase
TG Therapeutics announced a $100M share buyback program, allowing the company to purchase shares through open-market transactions. The program reflects its commitment to generating shareholder value.
New York, Sept. 02, 2025 — TG Therapeutics, Inc. (NASDAQ: TGTX) has announced a new share repurchase program worth up to $100 million. This move reflects the company's commitment to generating shareholder value and underscores its confidence in the current market conditions.The new program, authorized by the company's Board of Directors, will allow TG Therapeutics to buy back shares through open-market purchases and other transactions, in accordance with applicable securities laws and subject to market conditions. This initiative follows the successful completion of the company's previously authorized $100 million share repurchase program, which was completed in August 2025.
Under the completed program, TG Therapeutics repurchased approximately 3.5 million shares of its common stock at an average price of $28.55 per share. The new program aims to continue this trend by acquiring up to an additional $100 million of TG Therapeutics' common stock.
Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, "We are pleased to announce the completion of our previously authorized $100 million share repurchase program. In the month of August, we were able to repurchase approximately $78 million of TG stock at what we believe were highly attractive prices. In addition, our Board of Directors has authorized a new $100 million repurchase program, underscoring our continued commitment to delivering value to shareholders and reflecting our conviction that current market prices do not adequately reflect the multibillion-dollar potential of BRIUMVI or the long-term growth prospects of TG Therapeutics."
The share buyback program is a strategic move that could potentially increase earnings per share and provide investors with a higher return on investment. It also signals the company's confidence in its financial health and future growth prospects.
References:
[1] https://seekingalpha.com/news/4491936-tg-therapeutics-launches-100m-share-buybacks
[2] https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-completion-existing-share-repurchase
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet